yout 1 - Innovation2015

n
o
i
rd
3
Con l’adesione del Presidente della Repubblica
t
i
d
E
Scientific Programme
orkshop
Innovation in HIV
and Viral Hepatitis
Beyond viral undetectability:
new frontiers and strategies
Scientific Coordinators
Antonella d’Arminio Monforte (Milan, I)
Carlo Federico Perno (Rome, I)
Massimo Puoti (Milan, I)
Milan, Italy Palazzo delle Stelline
January 26-27, 2015
Depositato presso AIFA in data 08/05/14
orkshop
Innovation in HIV
and Viral Hepatitis
Beyond viral undetectability:
new frontiers and strategies
Endorsements
Ministero della Salute
Istituto Superiore di Sanità
Agenzia Italiana del Farmaco
Regione Lombardia
Università degli Studi, Milan
Dipartimento di Scienze della Salute, Università
degli Studi, Milan
Università degli Studi Tor Vergata, Rome
Azienda Ospedaliera San Paolo - Polo Universitario,
Milan
Azienda Ospedaliera Niguarda Ca’ Granda, Milan
Fondazione Policlinico Tor Vergata, Rome
SIMIT, Società Italiana Malattie Infettive e Tropicali
SIVIM, Società Italiana di Virologia Medica
AISF, Associazione Italiana per lo Studio del Fegato
AMCLI, Associazione Microbiologi Clinici Italiani
Fondazione AVIRALIA
Fondazione ICONA
ANLAIDS, Associazione Nazionale per la lotta
contro l’AIDS
EpaC Associazione Onlus
LILA, Lega Italiana per la lotta contro l’AIDS
Associazione NADIR
NPS Italia, Network Persone Sieropositive
Honorary President
Mauro Moroni
Professor Emeritus, University of Milan I
Scientific Coordinators
Antonella d’Arminio Monforte
San Paolo Hospital, University of Milan I
Carlo Federico Perno
University of Tor Vergata, Rome I
Massimo Puoti
Niguarda Ca’ Granda Hospital, Milan I
Scientific Secretariat
Francesca Ceccherini-Silberstein
University of Tor Vergata, Rome I
Giulia Marchetti
San Paolo Hospital, University of Milan I
Roberto Rossotti
Niguarda Ca’ Granda Hospital, Milan I
Faculty
Alessio Michele Aghemo Foundation IRCCS Maggiore
Hospital, University of Milan I
Massimo Galli Luigi Sacco Hospital, University of Milan I
Savino Bruno Fatebenefratelli Hospital, University Milan
Bicocca, Milan I
Giulia Marchetti San Paolo Hospital, University of Milan I
Alessia Maria Giorgini San Paolo Hospital, University of
Adriana Ammassari IRCCS - INMI Lazzaro Spallanzani, Milan I
Rome I
Enrico Girardi IRCCS - INMI Lazzaro Spallanzani, Rome I
Massimo Andreoni University of Tor Vergata, Rome I
Andrea Gori San Gerardo Hospital, Monza I
Gioacchino Angarano University Hospital of Bari I
Peter Hunt University of California, San Francisco USA
Mario Angelico University of Tor Vergata, Rome I
Paul Klenerman Nuffield Department of Medicine,
Andrea Antinori IRCCS - INMI Lazzaro Spallanzani,
University of Oxford UK
Rome I
Adriano Lazzarin University Vita-Salute San Raffaele,
Guido Antonelli University Hospital Umberto I and
Milan I
Sapienza University, Rome I
Massimo Levrero Sapienza University, Rome I
Stefano Bonora University of Turin I
Miriam Lichtner Sapienza University of Rome, Polo
Raffaele Bruno University of Pavia I
Pontino, Latina I
Andrea Calcagno University of Turin I
Giampiero Carosi Professor Emeritus, University of
Brescia I
Fabio Marra University of Florence I
Claudio Maria Mastroianni Sapienza University of
Rome, Polo Pontino, Latina I
Gabriele Missale University Hospital of Parma I
Antonella Castagna San Raffaele Scientific Institute,
Milan I
Mauro Moroni Professor Emeritus, University of Milan I
Dario Cattaneo Luigi Sacco Hospital, University of Milan I
Cristina Mussini University Hospital of Modena and
Reggio Emilia, Modena I
Francesca Ceccherini-Silberstein University of Tor
Vergata, Rome I
Carlo Federico Perno University of Tor Vergata, Rome I
Antonella Cingolani Catholic University, Rome I
Massimo Clementi University Vita-Salute San Raffaele,
Milan I
Massimo Colombo Foundation IRCCS Maggiore
Hospital, University of Milan I
Andrea Cossarizza University Hospital of Modena and
Reggio Emilia, Modena I
Antonella d’Arminio Monforte San Paolo Hospital,
University of Milan I
Gabriella d’Ettorre University Hospital Umberto I, Rome I
Massimo Pinzani Institute for Liver and Digestive Health,
University College London, Royal Free Hospital, London
UK
Teresa Maria Pollicino G. Martino University Hospital,
Messina I
Massimo Puoti Niguarda Ca’ Granda Hospital, Milan I
Giovanni Raimondo University Hospital of Messina I
Giuliano Rizzardini Luigi Sacco Hospital, University of
Milan I
Stefano Rusconi Luigi Sacco Hospital, University of
Milan I
Andrea De Luca Siena University Hospital, Siena I
Teresa Antonia Santantonio University Hospital of
Andrea De Maria University of Genoa, IRCCS AOU San Foggia I
Martino - IST Genoa I
Annalisa Saracino University Hospital of Bari I
Giovanni Di Perri University of Turin I
Guido Silvestri Emory University School of Medicine,
Daniel C. Douek Vaccine Research Center, National
Yerkes National Primate Research Center, Atlanta USA
Institute of Allergy and Infectious Diseases, National
Mario Strazzabosco University Milan Bicocca, Milan I
Institutes of Health, Bethesda USA
Valentina Svicher University of Tor Vergata, Rome I
Carlo Ferrari University Hospital of Parma I
Gloria Taliani Sapienza University, Rome I
Courtney V. Fletcher University of Nebraska Medical
Center, College of Pharmacy, Omaha USA
Camilla Tincati San Paolo Hospital, University of Milan I
Charles W. Flexner Johns Hopkins University, Baltimore
USA
Erica Villa University of Modena and Reggio Emilia,
Modena I
Giovanni Battista Gaeta Second University of Naples I
Massimo Zuin San Paolo Hospital, University of Milan I
5
orkshop
Innovation in HIV
and Viral Hepatitis
Beyond viral undetectability:
new frontiers and strategies
Scientific Programme January 26, 2015
11.00-11.10 Welcome addresses
11.10-11.20 Rationale and presentation of the Workshop
M. Moroni
A. d’Arminio Monforte, C.F. Perno, M. Puoti
11.20-12.20 OPENING LECTURES
Conveners: G. Antonelli, A. De Maria
11.20-11.40 Mechanisms of protection from SIV/HIV disease progression
11.40-12.00 Impact of HIV & HCV viral burden at population level:
what strategies to contain epidemics?
G. Silvestri
E. Girardi
M. Clementi, G.B. Gaeta, A. Lazzarin
12.00-12.20 Discussion
Mechanisms of viral persistence:
what role for the virus and what for the host?
12.20-13.40 SESSION 1
Conveners: G. Di Perri, M. Strazzabosco
12.20-12.40
12.40-13.00
13.00-13.20
13.20-13.40
HIV - What obstacles for the cure? The host vs the virus
HCV - Why the virus becomes chronic?
HBV - Why the virus becomes chronic?
Discussion
D.C. Douek
P. Klenerman
T.M. Pollicino
A.M. Aghemo, A. Cossarizza
13.40-14.30 Lunch and poster discussion
14.30-15.15 SESSION 2 Oral communications
Conveners: S. Bruno, C.M. Mastroianni
based on selected abstracts
PNPLA3 variant is an independent predictor of severe steatosis in patients with chronic
hepatitis C and HIV infection
C. Sagnelli1, M. Merli2, C. Uberti-Foppa2, N. Coppola3, H. Hasson2,1, G. Cirillo4, A. Gradone4,
S. Salpietro2, C. Minichini3, E. Miraglia Del Giudice4, A. Lazzarin2, E. Sagnelli3
1
Department Experimental Medicine and Surgery "F. Magrassi e A. Lanzara", Second University of Naples, Naples,
Italy; 2Department of Infectious Diseases, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy;
3Department of Mental Health and Public Medicine, Section of Infectious Diseases, Second University of Naples,
Naples, Italy; 4Department of Pediatrics, Second University of Naples, Naples, Italy
HIV-1 Impairs CD62L Expression and Function
L. Vassena, E. Giuliani, M. Doria
Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
Clonal Expansion of Infected Cells as a Mechanism of HIV Persistence
F. Simonetti1,2, S. Hill2, M. Gouzoulis2, W. Shao3, X. Wu3, M. Kearney3, S. Hughes3, J. Coffin3,
J. Mellors4, F. Maldarelli2
1
University of Milan, Milan, Italy; 2National Cancer Institute, Frederick, MD, USA; 3Leidos Biomedical Research,
Frederick, MD, USA; 4Tufts University, Boston, MA, USA; 5University of Pittsburg, PA, USA
6
January 26, 2015
HCV NS3 Quasispecies in Liver and Plasma and Dynamics of Telaprevir-resistant Variants
Assessed by UDPS in Breakthrough Patients: a Case Study
B. Bartolini, M. Selleri, A.R. Garbuglia, E. Giombini, G. D’Offizi, M.R. Capobianchi
National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy
Immune cytotoxic response selects a growing number of defective viral variants during the
natural history of HBV infection, some of which are not detectable in the periphery: possible
implications for the pathogenesis and for the clinical management of patients with chronic
hepatitis B
C. Minosse1, M. Selleri1, A. Baiocchini2, E. Giombini1, S. Coen1, P. Zaccaro1, G. Rozera1, D. Vincenti1,
U. Visco Comandini3, R. Lionetti3, M. Montalbano3, G. D'Offizi3, M.R. Capobianchi1, S. Menzo4
1
Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy; 2Laboratoy of Pathology,
National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy; 31st Clinical Division, National Institute for Infectious
Diseases "L. Spallanzani", Rome, Italy; 4Laboratory of Virology, Università Politecnica delle Marche, Ancona, Italy
A potential role of dendritic cell and monocytes assessment in predicting response to therapy
in HCV infected subjects
S. Vita1, M. Lichtner2, S. Savinelli1, C. Mascia1, T. Tieghi2, R. Marocco2, P. Zuccalà1, F. Schiavone1,
F. Mengoni1, V. Vullo1, C.M. Mastroianni2
1
Public Health and Infectious Diseases, Sapienza University, Rome, Italy; 2Infectious Diseases Unit, Sapienza
University, Polo Pontino, Latina, Italy
15.15-16.20 SESSION 3 Beyond
viral undetectability in plasma:
which markers of therapy outcome
Conveners: M. Colombo, G. Rizzardini
15.15-15.30 HIV - Case presentation and open questions
15.15-15.25 HIV case presentation
15.25-15.30 Open questions
G. d’Ettorre
P. Hunt
15.30-15.45 HCV - Case presentation and open questions
15.30-15.40 HCV case presentation
15.40-15.45 Open questions
F. Ceccherini-Silberstein
M. Zuin
15.45-16.00 HBV - Case presentation and open questions
15.45-15.55 HBV case presentation
15.55-16.00 Open questions
V. Svicher
G. Raimondo
16.00-16.20 Discussion
A. Gori, C. Mussini
16.20-16.35 Coffee break
16.35-18.25 SESSION 4 Eradication and
Conveners: A. Antinori, G. Carosi
16.35-16.45
16.45-17.05
17.05-17.25
17.25-17.45
17.45-18.05
18.05-18.25
functional cure: pharmacology
Framing the problem
Insight the HIV reservoirs
Insight the HCV-related cirrhosis
Long-Acting injectable ARVs: dream or reality?
Insight the HBV reservoirs
Discussion
7
A. Antinori
C.V. Fletcher
F. Marra
C.W. Flexner
M. Levrero
A. Calcagno, D. Cattaneo
orkshop
Innovation in HIV
and Viral Hepatitis
Beyond viral undetectability:
new frontiers and strategies
Scientific Programme January 27, 2015
09.00-09.30 LECTURE
Conveners: G. Angarano, M. Galli
09.00-09.20 CCR5 and modulation of fibrosis progression in HIV/HCV coinfection
09.20-09.30 Discussion
09.30-10.30 SESSION 5 Difficult to treat
Conveners: M. Andreoni, M. Angelico
R. Bruno
patients: what therapeutic strategy?
09.30-09.40 Framing the problem
M. Andreoni
09.40-09.55 High HIV viremia: case presentation and open questions
09.40-09.50 Does more aggressive anti HIV therapy work?
09.50-09.55 Open questions
C. Tincati
A. De Luca
09.55-10.10 HCV-related cirrhosis: case presentation and open questions
09.55-10.05 What treatment options for low HCV decay?
10.05-10.10 Open questions
10.10-10.30 Discussion
A.M. Giorgini
M. Pinzani
G. Missale, S. Rusconi
10.30-10.45 Coffee break
10.45-11.30 SESSION 6 Oral communications
Conveners: C. Ferrari, A. Saracino
based on selected abstracts
α +
Inherent transcriptional signatures of NK cells are associated with response to IFNα
ribavirin therapy in patients with Hepatitis C Virus
M.L. Ascierto1,2, F. Bozzano1,3, D. Bedognetti4, F. Marras5, C. Schechterly6, A. Picciotto7,
S. Marenco7, Y. Zhao8, V. De Giorgi6, M. Sommariva6, L. Moretta5, E. Wang4, H.J. Alter6,
F.M. Marincola4, A. De Maria1,3,7
1
Department of Health Sciences, University of Genoa, Italy; 2Department of Oncology, Johns Hopkins University,
Baltimore, MD, USA; 3Department of Experimental Medicine, University of Genoa, Italy; 4Sidra Medical and Research
Centre, Doha, Qatar; 5Istituto Giannina Gaslini, Genova, Italy; 6Department of Transfusion Medicine, Clinical Center
and Center of Human Immunology, National Institutes of Health, Bethesda, MD, USA; 7IRCCS Az. Osp. Univ. San
Martino-IST Istituto Nazionale Ricerca sul Cancro, Genova, Italy; 8Biometric Research Branch, Division of Cancer
Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Sofosbuvir-based all-oral treatment for elderly Chronic Hepatitis C patients: a costeffectiveness analysis
A. Ciaccio1, P.A. Cortesi2, G. Bellelli3, M. Rota4, M. Rota1, S. Okolicsanyi1, L.G. Mantovani2,
G. Annoni3, M. Strazzabosco1,5
1
Department of Surgery and Translational Medicine; 2Research Centre on Public Health (CESP); 3Department of
Health Sciences, Geriatric Medicine; 4Department of Health Sciences, Centre of Biostatistics for Clinical
Epidemiology, University of Milan-Bicocca, Milan, Italy; 5Liver Center & Section of Digestive Diseases, Department
of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
8
January 27, 2015
Peripheral and CSF immune-activation and inflammation are associated with elevated CSF
HIV–RNA in antiretroviral naïve HIV-infected individuals
E. Merlini1, F. Bai1, F. Iannuzzi1, M. Trunfio1, A. Calcagno2, S. Bonora2, E.S. Cannizzo1, M. Basilissi1,
G. Marchetti1 and A. d’Arminio Monforte1
1
University of Milan, Dept of Health Sciences, Italy; 2University of Turin, Italy
Final results of Telaprevir-based therapy in HCV/HIV patients with severe fibrosis
A. Gori1, M. Doroana2, O. Chernova3, J. Rockstroh4, D. Banhegyi5, C. Bergin6, G. Verucchi7,
R. DeMasi8, B. Hadacek9, M. Nelson10
1
Division of Infectious Diseases, San Gerardo Hospital, Monza, Italy; 2Servico de Doencas Infecciosas, Hospital de
Santa Maria, Lisbon, Portugal; 3State Healthcare Institution, Tolyatti, Russian Federation; 4Department of Internal
Medicine, University Hospital Bonn, Bonn, Germany; 5Szent Laszlo Hospital, Budapest, Hungary; 6Department of
Genitourinary Medicine and Infectious Diseases, St James Hospital, Dublin, Ireland; 7Division of Infectious Diseases,
University of Bologna, Bologna, Italy; 8Janssen Research and Development LLC, Titusville, NJ, USA; 9Janssen
Pharmaceuticals, Paris, France; 10Chelsea and Westminster Hospital, London, United Kingdom
Slow HCV kinetics following Sofosbuvir + Ribavirin administration in real-life setting of liver
transplant recipients with severe recurrent hepatitis C
V. Cento1, M.F. Donato2, I. Lenci3, M. Rendina4, V.C. Di Maio1, M. Milana3, S. Monico2, M. Aragri1,
R. Alfieri5, A. Abedrabbo3, D. Sforza6, M. Manuelli6, L. Mameli7, M.C. Sorbo1, R. Canu8, M.L. Ponti8,
C. Chialà4, F. Malinverno2, S. Marenco9, L. Milanesi5, A. Picciotto9, G. Rossi2, A. Di Leo4, G. Tisone6,
F. Zamboni7, R. Ganga8, M. Colombo2, C.F. Perno1,10, M. Angelico3, F. Ceccherini-Silberstein1
1
Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy; 2Gastroenterology and Liver
Transplant Units, Fondazione IRCCS Cà Granda Maggiore Hospital Policlinico and University of Milan, Milan, Italy;
3Hepatology Unit, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy; 4Gastroenterology and Digestive
Endoscopy, University Hospital, Policlinico Bari, Bari, Italy; 5Institute for Biomedical Technologies, National Research
Council, Segrate (MI), Italy; 6Liver Transplant Centre, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy;
7Liver Transplant Centre, Azienda Ospedaliera G Brotzu, Cagliari, Italy; 8Internal Medicine Unit, Azienda Ospedaliera
G Brotzu, Cagliari, Italy; 9Unit of Diagnosis and Therapy of Liver Diseases, “San Martino” Hospital, Genoa, Italy;
10Virology Unit, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy
11.30-13.20 SESSION 7 Infection and gender:
Conveners: A. Cingolani, T.A. Santantonio
11.30-11.40
11.40-12.00
12.00-12.20
12.20-12.40
12.40-13.00
13.00-13.20
any differences?
Framing the problem
Antiviral drug toxicity and pharmacokinetics
HIV: which biological differences according to gender?
HCV: natural history of chronic liver disease
The setting of HIV/HCV coinfection
Discussion
13.20-13.30 SESSION 8 Closing remarks
Conveners: A. d’Arminio Monforte, C.F. Perno, M. Puoti
9
A. Ammassari
S. Bonora
G. Marchetti
E. Villa
G. Taliani
A. Castagna, M. Lichtner
Selected Posters
1. Experience of acute hepatitis C and HIV co-infection
A. Iodice, V. Iodice
Azienda Ospedaliera Caserta, Italy
2. Differential Maturing Level of NK Cells Derived from HIV+ Patient Peripheral Blood CD34+ Cells
Compared with to NK Maturing from Cord Blood Precursors
F. Bozzano1,2, F. Marras3, G. Cenderello4, C. Dentone5, A. Di Biagio6, L.A. Nicolini6, C. Viscoli7, G. Bentivoglio3,
F. Antonini3, C. Cantoni3, M.L. Ascierto8,9, A. Moretta1,2, L. Moretta3, A. De Maria2,6
1
Department of Experimental Medicine, University of Genoa, Italy; 2Center of Excellence for Biomedical Research, University of
Genoa, Italy; 3G. Gaslini Institute, Genoa, Italy; 4Department of Infectious Diseases, Ospedali Galliera, Genoa, Italy; 5San Remo
Hospital, Imperia, Italy; 6IRCCS AOU San Martino-IST Genoa, Italy; 7Clinical Infectious Diseases, IRCCS AOU San MartinoIST Genoa, Italy; 8Department of Transfusion Medicine, Clinical Center and Center of Human Immunology, National Institutes of
Health, Bethesda, MD, USA; 9Department of Oncology, Johns Hopkins University, Baltimore, MD, USA
3. Distinct NK Cell Regulation in Virologically Discordant Non Progressor Patients, Addictional to EC/LTNP
F. Marras1, F. Bozzano2, A. Di Biagio3, L. Nicolini3, C. Viscoli3, C. Dentone4, E. Pontali5, S. Boni6, M. Setti3,7,
G. Orofino8, E. Mantia9, L. Moretta1, C. Orlandi10, A. Casabianca10, M. Magnani10, A. De Maria2,11
1
Istituto Giannina Gaslini, Genoa, Italy; 2Department of Experimental Medicine, DIMES, University of Genoa, Genoa, Italy;
Department of International Medicine and Infectious Disease IRCCS A.O.U. SanMartino-IST Genoa, Italy; 4Unità di Malattie
Infettive, Ospedale Sanremo, Sanremo (GE), Italy; 5Unità di Malattie Infettive, Ospedale Galliera, Genoa, Italy; 6Unità di Malattie
Infettive, Ospedale Sant’Andrea, La Spezia, Italy; 7Department of Internal Medicine, University of Genoa, Genoa, Italy; 8Unità di
Malattie Infettive, Ospedale Amedeo di Savoia, Turin, Italy; 9Unità di Malattie Infettive, Az. Osp. Santi A.B.C. Arrigo, Alessandria,
Italy;10Department of Biomolecular Science University of Urbino "Carlo Bo", Urbino (PU), Italy; 11Center of Excellence in
Biomedical Research, University of Genoa, Genoa, Italy
3
4. Proviral DNA and Inflammation during cART in Primary or Chronic Infection: ALPHA Study
G. Rozera, I. Abbate, C. Pinnetti, N. Orchi, P. Pierro, P. Lorenzini, A. Amendola, V. Bordoni, A. Antinori,
M.R. Capobianchi, A. Ammassari
National Institute for Infectious Disease “L. Spallanzani”, Rome, Italy
5. High levels of HBsAg with low plasmatic HBV-DNA in young African refugees with HBV genotype
infection: an indication for early treatment
V. Malagnino1, C. Sarrecchia1, C. Cerva1, V. Svicher2, M. Pollicita2, L. Colagrossi2, M. Aragri2, R. Salpini2,
A. Ricciardi1, G. MaffongelliI1, L. Dori1, C.F. Perno2, M. Andreoni1, L. Sarmati1
1
Clinic of Infectious Diseases, Policlinico Tor Vergata of Rome, Italy; 2Department of Experimental Medicine and Surgery,
University of Tor Vergata, Rome, Italy
6. Bone and Vascular Diseases in HIV Infected Patients: Is There a Link?
A. D’Abramo, M.A. Zingaropoli, A. Oliva, C. D’Agostino, M. Iannetta, G. d’Ettorre, M.R. Ciardi, C.M. Mastroianni,
V. Vullo
“Sapienza” University of Rome, Italy
7.
Impact of HCV RNA on Epidemiological, Viroimmunological, Clinical and Therapeutic Basal Features in
HIV/HCV Positive Subjects Enrolled in Master Cohort
M. Giralda1, P. Nasta1, F. Borghi1, A. Saracino2, F. Maggiolo3, S. Digiambenedetto4, M. Di Pietro5, L. Sighinolfi6,
A. Zoncada7, S. Costarelli8, F. Castelli1, G. Carosi9 and the MaSTER study group
1
University Division of Infectious and Tropical Diseases, University of Brescia, Italy; 2Infectious Diseases, Policlinico di Bari, Italy;
Infectious Diseases, Papa Giovanni XXIII Hospital, Bergamo, Italy; 4Infectious Diseases, Policlinico A. Gemelli - Catholic
University, Roma, Italy; 5Infectious Diseases, S.M. Annunziata Hospital, Firenze, Italy; 6Infectious Diseases, Nuovo Polo
Ospedaliero di Cona, Ferrara, Italy; 7Infectious Diseases, Istituti Ospitalieri, Cremona, Italy; 8Infectious Diseases, San Gerardo
Hospital, Monza, Italy; 9MISI Foundation, Italy
3
11
Selected Posters
8. Inflammatory myeloid subsets expansion in AIDS and non AIDS presenters
S. Savinelli1, M. Lichtner2, C. Mascia1, R. Rossi1, R. Marocco2, E.N. Cavallari1, G. d’Ettorre1, F. Schiavone2,
C.M. Mastroianni2, V. Vullo1
1
Department of Public Health and Infectious Diseases, University of Rome "Sapienza”, Italy; 2Infectious Diseases Unit, Polo
Pontino, University of Rome "Sapienza", Italy
9. Analysis of innate immune response in HCV mono-infected, HCV/HIV co-infected and HIV monoinfected patients under effective ART
F. Schiavone2, M. Lichtner1, C. Mascia2, S. Savinelli2, T. Tieghi1, R. Marocco1, S. Vita2, P. Zuccalà2, R. Rossi2,
F. Mengoni2, C.M. Mastroianni1, V. Vullo2
1
Infectious Diseases Unit, Sapienza University, Latina, Italy; 2Public Health and Infectious Diseases, Sapienza University, Rome,
Italy
10. A Web Portal for Clinical and Genotype Data Management for the Study of Hepatocellular Carcinoma
R. Alfieri1, M. Santoro2, M. Gnocchi1, M. Moscatelli1, O. Carpina3, C. Vischi3, C. Pisano4, V. De Murtas4,
E. Polilli5, F. P. Antonucci2, I. Maida4, P. Tarquini6, G. Garrucciu7, F. Bandiera8, D. Di Giammartino6, D. Laccabue9,
A. Olivani9, V. Borghi10, T. Quirino11, I. Lenci12, G. Tisone12, M. Angelico12, C. Mussini10, G. Rizzardini13,
M. Temponi3, G. Parruti5, M.S. Mura4, F. Ceccherini-Silberstein2, C.F. Perno2, L. Milanesi1
1
Istituto di Tecnologie Biomediche - CNR, Segrate (MI), Italy; 2Università degli Studi di Roma Tor Vergata, Roma, Italy; 3Flaconix,
Capriano Del Colle (BS), Italy; 4Università degli Studi di Sassari, Sassari, Italy; 5ASL Pescara PO Santo Spirito, Pescara, Italy;
6Ospedale G. Mazzini di Teramo, Italy; 7Azienda Ospedaliera Universitaria di Sassari, Italy; 8Ospedale Santissima Annunziata di
Sassari, Italy; 9Azienda Ospedaliera-Universitaria di Parma, Italy; 10Azienda Ospedaliero Universitaria di Modena Policlinico,
Italy; 11Azienda Ospedaliera Ospedale di Busto Arsizio (VA), Italy; 12Fondazione Policlinico Tor Vergata, Roma, Italy; 13Azienda
Ospedaliera e Polo Universitario Ospedale Luigi Sacco, Milano, Italy
11. Evaluation of Durability of 3 First-Line cART Regimens including Atazanavir/ritonavir,
Darunavir/ritonavir and Raltegravir in Patients Enrolled in a Large Italian Cohort (MASTER)
C. Torti1,3, A. Saracino2, C. Pezzoli3, C. Casari3, F. Maggiolo4, S. Digiambenedetto5, M. Di Pietro6, L. Sighinolfi7, A.
Zoncada8, S. Costarelli9, N. Mazzini11, M.C. Postorino1, M. Braggion10, G. Carosi11 and the MaSTER study group
1
Unit Operation Infectious Diseases, University of Magna Grecia, Catanzaro, Italy; 2Infectious Diseases, Policlinico di Bari, Italy;
Infectious Diseases, University of Brescia, Italy; 4Infectious Diseases, Papa Giovanni XXIII Hospital, Bergamo, Italy; 5Infectious
Diseases, Policlinico A. Gemelli - Catholic University, Rome, Italy; 6Infectious Diseases, S.M. Annunziata Hospital, Firenze, Italy;
7Infectious Diseases, Nuovo Polo Ospedaliero di Cona, Ferrara, Italy; 8Infectious Diseases, Istituti Ospitalieri, Cremona, Italy; 9Infectious
Diseases, San Gerardo Hospital, Monza, Italy; 10Foundation of Ca' Foscari University, Venice, Italy; 11MISI Foundation, Italy
3
13
General information
Workshop Venue
Palazzo delle Stelline
Corso Magenta, 61 - 20123 Milan, Italy
www.stelline.it
orkshop
Innovation in HIV
and Viral Hepatitis
Beyond viral undetectability:
orkshop
new frontiers and strategies
Innovation in HIV
and Viral Hepatitis
Beyond viral undetectability:
new frontiers and strategies
CME Provider and Organizing Secretariat
Effetti srl
Milan, Italy January 26-27, 2015
Via Gallarate, 106 - 20151 Milan, Italy
Phone +39 02 3343281 - Fax +39 02 38002105
Mail: [email protected]
Official language
English. No simultaneous translation provided.
CME accreditation
The Workshop has obtained 9 CME credits (ID number 150-112131) from Italian Health Ministry for the following professionals:
Medical Doctor, Biologist, Territory and Hospital Pharmacist, Nurse, Medical Laboratory Technician and Psychologist. Medical
specialties include: Infectious and Tropical Diseases, Hygiene, Epidemiology and Public Health, Microbiology and Virology, Allergology
and Clinical Immunology, Internal Medicine and Gastroenterology. Credits will be given only to participants attending 100% of the
teaching event and answering correctly to at least 75% of the final assessment questionnaire. Participants are also required to wear
the identification badge during working sessions, to provide their signature for attendance tracking purposes and to complete the
satisfaction questionnaire.
Poster session
Authors may post up their posters subject to registration. The selected posters should be affixed in the foyer outside Sala Volta (1st
floor), one hour before the beginning of the Workshop and taken away at the end of the scientific works. Posters should be prepared
in English. During poster discussion, authors are kindly requested to remain close to their own poster for answering questions.
Cyber point
A Cyber point is available at exhibition area in the foyer outside Sala Volta (1st floor).
Slide center
A slide center will be available to speakers, with computers, CD writer, printer and technical support. Only Powerpoint slide
presentations will be accepted. If a special equipment is needed, it should be communicated in advance to the Organizing Secretariat.
Slides must be submitted 2 hours before the scheduled presentation.
Technical equipment
Congress room is suitable for Powerpoint presentations and equipped with computers and overhead projectors. Speakers may not
use their own computers for their presentations.
Exhibition area
A technical-pharmaceutical and scientific publishing exhibition area will be open from 11:00 a.m. on Monday January 26th to 01:30
p.m. on Tuesday January 27th.
Web repository
Abstracts (oral and poster) and slide presentations of authors who provide their consent will be published on Workshop web site
(www.innovation2015.it) at the end of the event.
www.innovation2015.it
The Scientific Coordinators, the Scientific Secretariat and the CME Provider wish to thank for
support given in the form of unrestricted educational grants the following Companies:
PLATINUM SPONSOR
GOLD SPONSOR
OTHER SPONSORS
Supported by Gilead Sciences Europe Ltd who provided funding. Gilead Sciences Europe Ltd has
had no input into the content of the materials and presentations.

Download Report